Introduction of a biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis

Introduction of a biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis

Bespreek dit onderwerp op de HUB

De ZE&GG HUB is het samenwerkingsplatform voor alle aangesloten partijen van het programma ZE&GG.